Free
Case Reports  |   October 1997
Inhaled Nitric Oxide in Sickle Cell Disease with Acute Chest Syndrome 
Author Notes
  • (Atz) Assistant in Cardiology, Children's Hospital, and Instructor, Harvard Medical School.
  • (Wessel) Director, Cardiac Intensive Care Unit, Children's Hospital, and Associate Professor in Pediatrics (Anesthesia), Harvard Medical School.
  • Received from the Cardiac Intensive Care Unit, Children's Hospital, and the Departments of Cardiology, Pediatrics, and Anaesthesia, Harvard Medical School, Boston, Massachusetts. Submitted for publication March 4, 1997. Accepted for publication May 16, 1997.
  • Address reprint requests to Dr. Atz: Cardiac ICU Office, Children's Hospital, 300 Longwood Avenue, Farley 653, Boston, Massachusetts 02115. Address electronic mail to: atz@a1.tch.harvard.edu.
Article Information
Case Reports
Case Reports   |   October 1997
Inhaled Nitric Oxide in Sickle Cell Disease with Acute Chest Syndrome 
Anesthesiology 10 1997, Vol.87, 988-990. doi:
Anesthesiology 10 1997, Vol.87, 988-990. doi:
The acute chest syndrome (ACS), characterized by fever, chest pain, and radiographic evidence of new pulmonary infiltrate, effusion, or edema in patients with sickle cell disease is a significant cause of morbidity and death. [1 ] The often rapid resolution of severe ACS after exchange transfusion suggests that pulmonary vascular occlusion and ischemia and infarction play an important pathophysiologic role regardless of the etiology. [2 ] Recent appreciation of the importance of interactions between sickle erythrocytes and vascular endothelium has added to the understanding of the pathogenesis of vasoocclusion in sickle cell disease. [3–5 ] Inhaled nitric oxide has been demonstrated to selectively dilate the pulmonary circulation and to improve oxygenation when ventilation-perfusion inequalities exist. Inhaled nitric oxide may be especially useful in conditions where pulmonary vascular endothelial dysfunction is prominent. [6 ] We hypothesize that patients with ACS may represent a particular type of acute lung injury in which inhaled nitric oxide may improve oxygenation, cause specific pulmonary vasodilation, and potentially ameliorate the underlying vasoocclusive process.
Case 1 
A 4.5-yr-old boy with sickle cell disease was admitted with nonspecific abdominal pain and mild desaturation. Over 48 h, he developed increasing respiratory failure and hypoxia requiring mechanical ventilation and exchange transfusion, which reduced his percent sickle hemoglobin below 30%. An echocardiogram estimated right ventricular systolic pressure of 60 mmHg. Using high frequency oscillatory ventilation (mean airway pressure, 30 cm H2O; amplitude pressure, 52 cm H2O; rate, 10 Hz; FiO2, 0.90), arterial blood gas values were pH, 7.24; PCO2, 62; PaO2, 69; saturation, 94%. Oxygen saturation in the right atrium was 70%. After obtaining written informed consent from the parents, a trial of inhaled nitric oxide was performed according to a protocol approved by the Food and Drug Administration (FDA) and the Human Investigative Committee at Children's Hospital.
After 15 min of nitric oxide inhalation at 80 ppm, repeat measurements showed pH, 7.29; PCO2, 55; PaO2, 176; arterial oxygen saturation, 100%; and right atrial oxygen saturation, 81%. An echocardiogram now predicted right ventricular systolic pressure of 40 mmHg. The calculated intrapulmonary shunt fraction (Qs/Qt) decreased from 0.41 to 0.29.
Nitric oxide was decreased, and the patient's ventilator settings were reduced rapidly. Successful discontinuation of nitric oxide from 5 ppm after 92 h was associated with a transient, well-tolerated decrease in PaO2from 96 to 71 mmHg. The child was converted to a volume limited mode of ventilation and extubated uneventfully 4 days later. During nitric oxide therapy, nitrogen dioxide was <or= to 2ppm, and methemoglobin remained <or= to 0.3%
Case 2 
A 9-yr-old girl with sickle cell disease presented with a 3-day history of fever, cough, and back pain. She developed right lower and middle lobe infiltrates and right pleural effusion. A right-sided chest tube drained 300 cc of sterile serosanguinous pleural fluid. She developed increasing hypoxia with PaO2of 63 on 100% nonrebreathing mask. She was intubated, ventilated in a time-cycled, pressure-limited mode with peak inspiratory pressure of 32 cm H2O, end expiratory pressure of 10 cm H2O, rate of 14, FiO2of 0.5, and underwent exchange transfusion, which reduced the percent sickle hemoglobin below 30%. A Swan-Ganz catheter was placed, and measurements demonstrated pulmonary artery pressure, 54/31 mmHg; mean, 41 mmHg; wedge pressure, 11 mmHg; cardiac index, 5.15 l [center dot] min sup -1 [center dot] m sup -2; and calculated pulmonary vascular resistance, 5.8 U [center dot] m sup 2. She met institutional criteria for the use of inhaled nitric oxide, and parents gave written informed consent.
After 15 min of nitric oxide inhalation at 80 ppm, the pulmonary artery pressure was 37/18, mean was 26 mmHg, wedge was 12 mmHg, cardiac index was 6.43 l [center dot] min sup -1 [center dot] m sup -2, and pulmonary vascular resistance was 2.2 U [center dot] m2. There was improvement in PaO2from 107 to 185 mmHg. After 47 h, nitric oxide was discontinued without clinical changes. The child subsequently weaned and was extubated 2 days later. Maximal nitrogen dioxide and methemoglobin levels were <or= to 2 ppm and <or= to 0.5%, respectively.
Discussion 
We describe patients with sickle cell disease who developed acute chest syndrome with respiratory failure and pulmonary hypertension despite aggressive medical therapy including positive pressure ventilation and exchange transfusion. Inhaled nitric oxide resulted in rapid and significant pulmonary vasodilation and improved oxygenation. Prolonged therapy with inhaled nitric oxide was safely performed and may have been an important factor in the successful weaning and extubation of both patients.
The overall prognosis for patients with sickle hemoglobinopathies has continued to improve. However, a large proportion of deaths occur during an episode of ACS. [1 ] The specific inciting etiology of ACS is difficult to discern. Infections, fat embolism, and hypoventilation-atelectasis accompany and enhance intravascular sickling and vascular occlusion. The vasooclusive manifestations of sickle cell disease involve a complex and dynamic sequence of events in the microcirculation. Any change in the vessel tone that would either facilitate the passage of sickled red cells or hasten the passage of cells about to sickle would reduce vascular obstruction, although systemic vasodilator therapy can be dangerous, and fatal hypotension with small bowel infarction has been reported in a patient with ACS. [7 ]
Sickled red cells interfere with endothelium-dependent vasorelaxation, possibly by inhibition of nitric oxide. [5 ] They are more adherent to cultured endothelial cells than are normal red cells, [8 ] and they are able to accelerate the clotting process in vitro. [9 ] Exposure of human endothelial cells to previously sickled red cells resulted in a four- to eightfold transcriptional induction of the gene coding for the vasoconstrictor endothelin. Elevation of local nitric oxide levels by nitric oxide donors attenuated basal and sickle cell induced expression of endothelin transcripts. [4 ]
Additionally mononuclear cells from sickle cell disease patients release more superoxide than healthy control subjects in vitro. [10 ] Considering that superoxide produces oxidant damage and inhibits the pharmacologic actions of nitric oxide, this greater production may represent an additional risk factor for the obstruction of the microcirculation and tissue damage in these patients.
Inhaled nitric oxide has shown variable improvements in oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Selective pulmonary vasodilation may be most pronounced in patients with the greatest degree of pulmonary vasoconstriction [11 ] and baseline pulmonary vascular resistance may be the best marker predicting beneficial response to inhaled nitric oxide. [12 ] Inhibition of platelet aggregation has been suggested as an additional beneficial effect of nitric oxide in respiratory failure. [13 ] The response to nitric oxide in the sickle cell disease population may be exaggerated compared with others with respiratory failure due to a greater degree of baseline pulmonary hypertension, overproduction of vasoconstrictors, inhibition of endothelium-derived vasorelaxation, and acceleration of the clotting process. Our institutional protocol includes an initial 15-min trial of nitric oxide at 80 ppm followed by rapid reduction in the dose. Although our patients incurred no toxic side effects during our study, optimal dosage of nitric oxide may vary with each patient and the biologic circumstance, which was not addressed in this study.
Approximately 80–90% of inhaled nitric oxide is absorbed into the bloodstream and reacts with hemoglobin within the erythrocyte to form first nitrosylhemoglobin and then methemoglobin. [14 ] The heme tetramer in nitrosyl-hemoglobin is locked in the relaxed conformation and is unable to polymerize when the sickle mutation is present. [15 ] As red cells pass through small arterioles in the lung exposed to nitric oxide, significant amounts of nitrosyl-hemoglobin may form and reduce the amount of sickle polymerization as deoxygenation occurs.
Inhaled nitric oxide may therefore be beneficial in patients with ACS by dilating the pulmonary vascular bed, reducing afterload on the right ventricle, redistributing pulmonary blood flow to better ventilated areas of lung, and potentially reducing sickling in the lung. Proper large prospective trials will need to be undertaken to further elucidate the importance of this novel therapy in ACS. Early use of inhaled nitric oxide in this group of patients may decrease the incidence of ACS or reduce the need for more aggressive therapies such as exchange transfusion or mechanical ventilation.
References 
References 
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP: Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-44.
Emre U, Miller ST, Gutierez M, Steiner P, Rao SP, Rao M: Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995; 127:901-4.
Natarajan M, Udden MM, McIntire LV: Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Blood 1996; 87:4845-52.
Phelan M, Perrine SP, Brauer M, Faller DV: Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 1995; 96:1145-51.
Mosseri M, Bartlett-Pandite AN, Wenc K, Isner JM, Weinstein R: Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J 1993; 126:338-46.
Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ: Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993; 88(part I):2128-38.
Hammond TG, Mosesson MW: Fatal small-bowel necrosis and pulmonary hypertension in sickle cell disease. Arch Intern Med 1989; 149:447-8.
Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW: Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: Possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest 1980; 65:154-60.
Chiu D, Lubin B, Roelofsen B, van Deenen LL: Sickled erythrocytes accelerate clotting in vitro: An effect of abnormal membrane asymmetry. Blood 1981; 58:398-401.
Dias-Da-Motta PM, Arruda VR, Muscara MN, Saad ST, De Nucci G, Costa FF, Condino-Neto A: The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. Br J Haematol 1996; 93:333-40.
Bigatello LM, Hurford WE, Kacmarek RM, Roberts JDJ, Zapol WM: Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Anesthesiology 1994; 80:761-70.
Lowson SM, Rich GF, McArdle PA, Jaidev J, Morris GN: The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesth Analg 1996; 82:574-81.
Samama CM, Diaby M, Fellahi J, Mdhafar A, Eyraud D, Arock M, Guillosson JJ, Coriat P, Rouby JJ: Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1995; 83:56-65.
Yoshida K, Kasama K: Biotransformation of nitric oxide. Envir Health Persp 1987; 73:201-5.
Jongeward KA, Magde D, Taube DJ, Marsters JC, Traylor TG, Sharma VS: Picosecond and nanosecond geminate recombination of myoglobin with CO, O sub 2, NO, and isocyanides. J Am Chem Soc 1988; 110:380-7.